Contents

Preface *XIII*

1 The Aims and Structure of Regulations *1*
1.1 Introduction *1*
1.2 Purpose and Principles of Regulation *1*
1.3 The Legal Framework for Regulation *3*
1.3.1 National Legislative Process *3*
1.3.2 EU Legislative Process *4*
1.3.3 Working with Legal Texts *5*
1.3.4 Guidance Documents *6*
1.3.5 Pharmacopoeia *7*
1.4 Basic Legislation *7*
1.4.1 EU Legislation *7*
1.4.2 US Legislation *11*
1.5 Scope of the Legislation *16*
1.6 Chapter Review *19*
1.7 Further Reading *19*

2 Regulatory Strategy *21*
2.1 Chapter Introduction *21*
2.2 Basic Regulatory Strategy *21*
2.2.1 Product Development *21*
2.2.2 Product Manufacture *21*
2.2.3 Market Vigilance *22*
2.3 Quality Assurance Systems *22*
2.3.1 Personnel *23*
2.3.2 Documentation *24*
2.3.3 Facilities and Equipment *25*

Medical Product Regulatory Affairs. John J. Tobin and Gary Walsh
Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim
ISBN: 978-3-527-31877-3

2.3.4 Corrective and Preventive Action *25*
2.4 Validation *26*
2.5 Regulatory Bodies *27*
2.5.1 European Commission *27*
2.5.2 The EMEA *29*
2.5.3 National Competent Authorities *30*
2.5.4 Notified Bodies *32*
2.5.5 The FDA *32*
2.5.6 US Department of Agriculture *35*
2.5.7 Pharmacopoeia Authorities *36*
2.6 International Harmonisation Bodies *36*
2.7 International Conference on Harmonisation *36*
2.7.1 VICH *39*
2.7.2 The Global Harmonisation Task Force *39*
2.8 Pharmaceutical Inspection Cooperation Scheme *40*
2.9 The World Health Organization (WHO) *42*
2.10 Chapter Review *42*
2.11 Further Reading *42*

3 Drug Discovery and Development *43*
3.1 Chapter Introduction *43*
3.2 Drug Categorisation *43*
3.2.1 Prescription Status *43*
3.2.2 Physical Properties *44*
3.2.3 Mode of Action *44*
3.2.4 Therapeutic Use *45*
3.3 Drug Discovery *45*
3.4 Drug Development *50*
3.5 Drug Delivery *52*
3.5.1 Location *52*
3.5.2 Drug Characteristics *52*
3.5.3 Speed and Duration of Therapeutic Effect *53*
3.5.4 Stability *55*
3.6 Chapter Review *55*
3.7 Suggested Reading *55*

4 Non-Clinical Studies *57*
4.1 Chapter Introduction *57*
4.2 Non-Clinical Study Objectives and Timing *57*
4.3 Pharmacological Studies *58*
4.3.1 Pharmacodynamic Studies *59*
4.3.2 Pharmacokinetic/Toxicokinetic Studies *62*
4.4 Bioavailability and Bioequivalence *64*
4.5 Toxicology Studies *65*

4.5.1 Toxicity Studies *65*
4.5.2 Genotoxicity Studies *66*
4.5.3 Carcinogenicity Studies *67*
4.5.4 Reproductive Toxicology Studies *67*
4.6 Chemistry, Manufacturing and Control Development (CMC) *67*
4.7 Quality of Biotech Products *68*
4.7.1 Stability Studies *68*
4.8 Good Laboratory Practice (GLP) *69*
4.9 Chapter Review *69*
4.10 Further Reading *71*

5 Clinical Trials *73*
5.1 Chapter Introduction *73*
5.2 Clinical Trials *73*
5.2.1 Phase I Trials *74*
5.2.2 Phase II Trials *74*
5.2.3 Phase III Trials *75*
5.3 Clinical Trial Design *76*
5.4 Good Clinical Practice *78*
5.5 Clinical Trials in the EU *78*
5.5.1 The Sponsor *80*
5.5.2 The Investigator's Brochure *80*
5.5.3 The Investigator *81*
5.5.4 The Trial Protocol *81*
5.5.5 The Investigational Medicinal Product Dossier *82*
5.5.6 Informed Consent *82*
5.5.7 Manufacture of Investigational Medicinal Product *82*
5.5.8 Competent Authority Clinical Trial Application *84*
5.5.9 Independent Ethics Committee CTA *85*
5.5.10 Amendments to Clinical Trials *87*
5.5.11 Case Report Forms *87*
5.5.12 Adverse Event Reporting *87*
5.5.13 Annual Safety Report *88*
5.5.14 Monitoring of Trials *88*
5.5.15 End of Trial *88*
5.5.16 Trial Master File *88*
5.6 Clinical Trials in The US *89*
5.6.1 Investigational New Drug Application (IND) *89*
5.6.2 Institutional Review Board *91*
5.6.3 Communication with the FDA *94*
5.6.4 Labelling of Investigational Drugs *95*
5.7 Chapter Review *95*
5.8 Further Reading *95*

6 Marketing Authorisation *97*
6.1 Chapter Introduction *97*
6.2 The Application Dossier *97*
6.3 CTD *98*
6.3.1 Module Structure *101*
6.3.2 Module 3: Quality *101*
6.3.3 Drug Master Files *104*
6.3.4 Module 4: Non-Clinical Study Reports *105*
6.3.5 Module 5: Clinical Study Reports *105*
6.3.6 Module 2: Summaries *107*
6.3.7 Module I: Region-Specific *110*
6.3.8 Module 1: EU *110*
6.3.9 Module 1: US *113*
6.4 Submission and Review Process in the EU *114*
6.4.1 Community Authorisation *114*
6.4.2 Scientific Evaluation Process *119*
6.4.3 Decision-Making Process *120*
6.4.4 National Authorisations *121*
6.4.5 Decentralised Procedure *121*
6.4.6 Mutual Recognition Procedure *123*
6.4.7 Plasma Master Files and Vaccine Antigen Master Files *124*
6.5 Submission and Review Process in the US *124*
6.6 Chapter Review *127*
6.7 Further Reading *127*

7 Authorisation of Veterinary Medicines *129*
7.1 Chapter Introduction *129*
7.2 Overview of Development Process for Veterinary Medicines *129*
7.2.1 Pre-Clinical Studies *130*
7.2.2 Clinical Trials *131*
7.2.3 Good Clinical Practices *131*
7.3 Authorisation of Clinical Trials in the EU *134*
7.4 Authorisation of Clinical Trials in the US *135*
7.5 Maximum Residue Limits *136*
7.6 Authorisation of Veterinary Medicines in the EU *138*
7.6.1 Applications to Establish MRLs *138*
7.6.2 Review of Applications and Establishment of MRLs *138*
7.6.3 Marketing Authorisations *142*
7.6.4 Presentation of the Dossier *143*
7.7 Approval of Veterinary Medicines in the US *144*
7.7.1 New Animal Drug Application *144*
7.7.2 Approval of Veterinary Biological Products *147*
7.8 Chapter Review *148*
7.9 Further Reading *148*

8 Variations to the Drug Authorisation Process *149*
8.1 Chapter Introduction *149*
8.2 Provisions in Support of Special Drug Applications *149*
8.2.1 Orphan Drugs *149*
8.3 Accelerated Access to New Drug Therapies *151*
8.3.1 EMEA Accelerated Review *151*
8.3.2 Compassionate Use *151*
8.3.3 Fast-Track Products *152*
8.3.4 Treatment INDs *152*
8.3.5 Paediatric Applications *152*
8.4 Approval of New Drugs when Human Efficacy Studies are not Ethical or Feasible *153*
8.5 Animal Drugs for Minor Use and Minor Species *153*
8.5.1 Conditional Approval *153*
8.5.2 Indexing *154*
8.5.3 Designation *154*
8.6 Use of Non-Authorised Drugs for Animal Treatment in the EU *154*
8.7 Changes to an Authorised Drug *154*
8.8 EU System for Processing Changes *154*
8.8.1 Extension Applications *155*
8.8.2 Major Variation (Type II) *155*
8.8.3 Minor Variation (Type IA or IB) *156*
8.9 Processing Changes in the US *156*
8.9.1 Manufacturing Change Supplements *156*
8.9.2 Major Changes *157*
8.9.3 Moderate Changes *157*
8.9.4 Minor Changes *157*
8.10 Authorisation of Generic Drugs *158*
8.10.1 EU Regulations *158*
8.10.2 US Regulations *159*
8.11 Reference Drug Exclusivity *159*
8.12 Other Authorisation Procedures *161*
8.12.1 Well-Established Medical Use Products *161*
8.12.2 Combination Products *161*
8.12.3 Homeopathic Medicines *161*
8.12.4 Traditional Herbal Medicines *162*
8.12.5 US Regulation of OTC Drugs *162*
8.13 Chapter Review *164*
8.14 Further Reading *164*

9 Medical Devices *167*
9.1 Chapter Introduction *167*
9.2 Regulatory Strategy for Medical Devices in the EU *167*
9.2.1 Use of Standards to Establish Conformity *168*
9.2.2 Classification of Devices *170*

9.3 Regulatory Strategy for Medical Devices in the US *173*
9.3.1 Classification of Devices *173*
9.3.1.1 Class I Devices *176*
9.3.1.2 Class II Devices *177*
9.3.1.3 Class III Devices *178*
9.3.2 Classification of New Devices *178*
9.4 Development of Devices *178*
9.4.1 Design Controls *180*
9.4.2 Design and Development Planning *180*
9.4.3 Design Input *182*
9.4.4 Design Output *182*
9.4.5 Design Verification and Design Validation *183*
9.4.6 Design Review *183*
9.4.7 Risk Analysis *184*
9.4.8 Design Changes *185*
9.5 Chapter Review *185*
9.6 Further Reading *185*

10 Authorisation of Medical Devices *187*
10.1 Chapter Introduction *187*
10.2 Evaluation of Medical Devices in Europe *187*
10.2.1 Clinical Investigations *188*
10.2.2 Performance Evaluations *190*
10.3 Evaluation of Medical Devices in the US *191*
10.3.1 IDE-Exempted Investigations *191*
10.3.2 Abbreviated Requirement Investigations *192*
10.3.3 IDE Investigations *192*
10.3.4 Labelling of Devices for Investigational Use *193*
10.4 Placing of Devices on the Market in the EU *194*
10.4.1 Conformity Assessment Procedures *195*
10.4.2 Full Quality Assurance *197*
10.4.3 EC Type-Examination *197*
10.4.4 Production Quality Assurance *199*
10.4.5 EC Verification *199*
10.4.6 Product QA *199*
10.4.7 EC (Self) Declaration of Conformity *199*
10.4.8 Technical Documentation *199*
10.4.9 Labelling Requirements *200*
10.4.10 Competent Authority Notifications and the European Databank *201*
10.5 Placing of Devices on the Market in the US *202*
10.5.1 510(k) Pre-market Notification *202*
10.5.1.1 Traditional 510(k) *202*
10.5.1.2 Abbreviated 510(k) *203*
10.5.1.3 Special 510(k) *203*
10.5.1.4 De Novo 510(k) *203*

10.5.2 Notification and Review Procedures *203*
10.5.3 Pre-market Approval (PMA) *203*
10.5.4 Changes to a PMA-Approved Device *205*
10.5.5 Humanitarian Use Devices *206*
10.5.6 Labelling of Devices *206*
10.6 Chapter Review *206*
10.7 Further Reading *208*

11 Good Manufacturing Practice (GMP) *209*
11.1 Chapter Introduction *209*
11.2 Drug GMP Regulations and Guidance *209*
11.3 Essential GMP Requirements *212*
11.3.1 Quality Assurance System *212*
11.3.2 Personnel *212*
11.3.3 Premises and Equipment *213*
11.3.4 Documentation *221*
11.3.5 Production *222*
11.3.6 Quality Control *222*
11.3.7 Work Contracted Out *222*
11.3.8 Complaints, Product Recall and Emergency Un-Blinding *223*
11.3.9 Self-Inspection *223*
11.4 Validation *223*
11.4.1 Facilities and Equipment Validation *225*
11.4.2 Process Validation *225*
11.4.3 Computer Systems Validation *226*
11.4.4 Methods Validation *227*
11.4.5 Cleaning Validation *229*
11.4.6 Validation of Sterilisation Procedures *230*
11.4.7 Water Purification System Validation *230*
11.5 GMP Requirements for Devices *231*
11.6 Chapter Review *234*
11.7 Further Reading *235*

12 Oversight and Vigilance *237*
12.1 Chapter Introduction *237*
12.2 Registration of Manufacturers and Other Entities *237*
12.3 Manufacturing Authorisation of Medicinal Products in the EU *237*
12.3.1 Wholesale Distribution of Medicinal Products *238*
12.3.2 Registration of Persons Responsible for Placing Medical Devices on the EU Market *240*
12.4 Registration of Producers of Drugs and Devices in the US *241*
12.4.1 Additional Licensing Requirements *242*
12.5 Inspections *242*
12.5.1 Inspection Techniques *245*
12.5.2 Audit Findings and Consequences *248*

12.6 Market Vigilance and Oversight of Drugs *253*
12.6.1 Pharmacovigilance in the EU *254*
12.6.2 Qualified Person *254*
12.6.3 Reporting Requirements *254*
12.6.4 Expedited Reports *255*
12.6.5 Periodic Safety Update Reports *256*
12.6.6 Safety Study Reports *256*
12.6.7 Response to Issues *256*
12.6.8 Renewal of Marketing Authorisations *258*
12.6.9 Reporting Requirements in the US *258*
12.6.10 Expedited Reports *258*
12.6.11 Periodic Reports *262*
12.7 Advertising and Promotion *262*
12.8 Market Vigilance and Oversight of Devices *262*
12.8.1 Market Vigilance in the EU *263*
12.8.2 Medical Device Vigilance in the US *271*
12.8.3 Medical Device Reporting *272*
12.8.4 Reports of Corrections and Removals *273*
12.8.5 Post-Market Surveillance *273*
12.9 Chapter Review *274*
12.10 Further Reading *274*

Index *277*